These results highlight potential efficacy of drugs targeting PI3K, AKT, MEK, ERK, EGFR, and PDGFRA, as well as APP, ESR1, SMARCA2, HDAC9, AURKC, and NAMPT in selected gliomas. This evidence concerns the gene HDAC9 and glioma.